Table 4. Experiences with targeted and... | American Society of Hematology

Table 4.

Experiences with targeted and novel agents in marginal zone lymphomas

Study	Drug	Setting	Patients	ORR %	CR %	Median PFS, mo
Vanazzi et al⁴⁹	⁹⁰Y-ibritumomab tiuxetan	MALT relapsed	30	90	77	Not reached*
Samaniego et al⁵⁰	⁹⁰Y-ibritumomab tiuxetan	MALT de novo	11	100	—	Not reached
Lossos et al⁵¹	⁹⁰Y-ibritumomab tiuxetan	MZL de novo	16	88	56	47.6
Lolli et al ⁵²	⁹⁰Y-ibritumomab tiuxetan	MALT de novo+relapsed	16	94	63	37.3
Zinzani et al ⁵³	Chemotherapy+⁹⁰Y-ibritumomab tiuxetan	MZL de novo	10	90	90	—
Kiesewetter et al ⁵⁵	Lenalidomide	MALT de novo+relapsed	18	61	33	—
Kiesewetter et al ⁵⁶	Lenalidomide+rituximab	MALT de novo+relapsed	46	80	54	—
Becnel et al ⁵⁹	Lenalidomide+rituximab	MZL de novo	30	93	70	59.8
Noy et al ⁶¹	Ibrutinib	MZL relapsed	63	48	3	14.2
Gopal et al ⁶²	Idelalisib	MZL relapsed	15	47	7	7.0
Flinn et al ⁶³	Duvelisib	MZL relapsed	18	39	—	—
Dreyling et al ⁶⁴	Copanlisib	MZL relapsed	23	70	9	—
Forero-Torres et al ⁶⁵	Parsaclisib	MZL relapsed	9	78	33	—
Zinzani et al ⁶⁶	Umbralisib	MZL relapsed	69	55	10	71%†

Study	Drug	Setting	Patients	ORR %	CR %	Median PFS, mo
Vanazzi et al⁴⁹	⁹⁰Y-ibritumomab tiuxetan	MALT relapsed	30	90	77	Not reached*
Samaniego et al⁵⁰	⁹⁰Y-ibritumomab tiuxetan	MALT de novo	11	100	—	Not reached
Lossos et al⁵¹	⁹⁰Y-ibritumomab tiuxetan	MZL de novo	16	88	56	47.6
Lolli et al ⁵²	⁹⁰Y-ibritumomab tiuxetan	MALT de novo+relapsed	16	94	63	37.3
Zinzani et al ⁵³	Chemotherapy+⁹⁰Y-ibritumomab tiuxetan	MZL de novo	10	90	90	—
Kiesewetter et al ⁵⁵	Lenalidomide	MALT de novo+relapsed	18	61	33	—
Kiesewetter et al ⁵⁶	Lenalidomide+rituximab	MALT de novo+relapsed	46	80	54	—
Becnel et al ⁵⁹	Lenalidomide+rituximab	MZL de novo	30	93	70	59.8
Noy et al ⁶¹	Ibrutinib	MZL relapsed	63	48	3	14.2
Gopal et al ⁶²	Idelalisib	MZL relapsed	15	47	7	7.0
Flinn et al ⁶³	Duvelisib	MZL relapsed	18	39	—	—
Dreyling et al ⁶⁴	Copanlisib	MZL relapsed	23	70	9	—
Forero-Torres et al ⁶⁵	Parsaclisib	MZL relapsed	9	78	33	—
Zinzani et al ⁶⁶	Umbralisib	MZL relapsed	69	55	10	71%†

Time-to-treatment failure.

†PFS percentage at 12 months.